Gilead Sciences (GILD) Offering Possible 11.11% Return Over the Next 9 Calendar Days

Gilead Sciences's most recent trend suggests a bearish bias. One trading opportunity on Gilead Sciences is a Bear Call Spread using a strike $74.50 short call and a strike $80.00 long call offers a potential 11.11% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $74.50 by expiration. The full premium credit of $0.55 would be kept by the premium seller. The risk of $4.95 would be incurred if the stock rose above the $80.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Gilead Sciences is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Gilead Sciences is bearish.

The RSI indicator is at 58.29 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Gilead Sciences

New Data on Gilead’s Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults
Mon, 09 Mar 2020 18:53:00 +0000
Gilead Sciences Inc. (Nasdaq: GILD) today announced data from the BRAAVE 2020 study, a Phase 3 clinical trial evaluating the safety and efficacy of switching to Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, BIC/FTC/TAF) in virologically suppressed adults living with HIV who self-identified as Black or African American. The data show that, at 24 weeks, switching to Biktarvy from a standard regimen of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent may potentially be an effective and well-tolerated treatment regimen in patients with a history of treatment failure or pre-existing resistance, and did not result in treatment emergent resistance to study drugs with Biktarvy. The use of Biktarvy in individuals with a history of treatment failure or known resistance to the components of Biktarvy is investigational.

Two Companies Are Making Progress on Coronavirus Treatments. The Stocks Aren’t Responding.
Mon, 09 Mar 2020 18:48:00 +0000
Gilead Sciencesand Regeneron Pharmaceuticals are both making progress in developing treatments for coronavirus.

Stocks To Watch: Gilead Sciences Sees RS Rating Rise To 93
Mon, 09 Mar 2020 16:51:00 +0000
On Monday, Gilead Sciences received an upgrade to its Relative Strength (RS) Rating, from 90 to 93. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

High-Flying Gilead Slides Amid RBC Downgrade and Market Rout
Mon, 09 Mar 2020 16:01:00 +0000
While RBC notes it expects 'further upside' from Gilead, analysts at the firm are growing wary of the relatively high valuation of the drug development company's share price.

GSK's HIV combo treatment meets main goal in late-stage study
Mon, 09 Mar 2020 15:13:14 +0000
GlaxoSmithKline PLC's unit ViiV Healthcare said on Monday its two-drug regimen to treat HIV was as effective in patients given the treatment every two months, as when administered once a month. The drug, Cabenuva, the long-acting injectable two-drug regimen of antiviral compounds cabotegravir and Johnson & Johnson's rilpivirine, met the main goal at the end of 48 weeks. “This two-drug regimen may provide an opportunity for people living with HIV to break the cycle of taking a daily pill and reduce their total treatment dosing days from 365 to six,” Kimberly Smith, head of research and development, said.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.